A trial of a non-prescription migraine medication resulted in relieving the pain of over 60% of patients within two hours of taking the drug.
According to a recent announcement made by PuraMed BioScience, Inc., a clinical study on PuraMed's non-prescription migraine medication LipiGesic™ M relieved the pain of over 60% of the patients involved within two hours of taking the drug.
These findings will be presented at the 2011 Headache Update Conference, which will be held at Disney's Grand Floridian Resort & Spa in Orlando from July 14th to 17th, 2011.
Lead researcher, Dr. Roger Cady, conducted a multi-site, double-blind, placebo controlled clinical trial which was performed at three headache centers in the United States.
The study is titled "A Double-Blind Placebo-Controlled Pilot Study of Sublingual Feverfew and Ginger (LipiGesic™ M) in the Treatment of Migraine.”
The study discovered that 64% of participants involved achieved pain relief within two hours of taking LipiGesic M.
The researchers also found that the study found sublingual feverfew/ginger to be as safe and effective as a first-line treatment for a population of migraineurs who often suffer from small headaches before the commencement of moderate to severe migraines.
It is anticipated that Cady’s presentation will be given to over 300 primary care providers and specialists attending the 2011 Headache Update Conference; the attendees will include physicians specializing in anesthesia, OB-GYN, pain and addiction, internal medicine, pediatrics, ENT, neurology, emergency medicine, hospitalists and psychiatry.
Along with the specialists there will also be pharmacists and other health care professionals there, all of whom are responsible for diagnosing and helping manage headaches, migraines, and other chronic pain in patients.
"This will be a very important meeting for PuraMed BioScience, Inc. because of the interest elicited by Dr. Cady's recently published independent clinical study of LipiGesic M," reported Russell Mitchell, PuraMed BioScience CEO. "This is an excellent opportunity for us to introduce and further discuss our product and study with many of the leading headache specialists in the U.S."
The study was recently published online in Headache, and is anticipated to be published in the printed version shortly.